Novartis Makes Donation to Cystic Fibrosis Worldwide to Support Education
Novartis donates 20,000 EURO to support the Cystic Fibrosis Worldwide Education program. In 2011 CFW will partner with thier member, CF Saudi Arabia to bring the first of its kind CF conference to the Middle East.
(PRWEB) September 24, 2011
Novartis, a healthcare solutions company headquartered in Switzerland, has donated 20,000 EURO to Cystic Fibrosis Worldwide (CFW) education programs headed by Dr. Harry Heijerman.
The Cystic Fibrosis Worldwide education team is comprised of seven top medical and allied health professionals from around the world who specialize in cystic fibrosis. These professionals, along with Dr. Heijerman, are the foundation of the education programs. Dr. Heijerman is the founding editor of the Cystic Fibrosis Journal, founding member of the European CF Society, Director of the Hague Teaching Hospital Adult Pulmonology Department and a medical advisor to the World Health Organization Human Genetics Program.
Cystic Fibrosis Worldwide offers education programs for practicing clinicians, allied healthcare professionals and patients and families. These programs are available to a global audience and are targeted to developing countries. To date, Cystic Fibrosis Worldwide educates over 2000 clinicians, healthcare professionals and patients and families annually.
The organization utilizes a variety of education mediums to spread information about cystic fibrosis. The network of live, interactive, online and print educational materials is able to reach a wide audience. The organization strives to make these materials available at zero to low costs. In addition, CFW provides these materials in over 15 different languages.
In December 2011, Cystic Fibrosis Worldwide will host in partnership with the Royal King Faisal Specialist Hospital & Research Centre, an educational conference in Saudi Arabia. The event will feature workshops and lectures by the CFW education team as well as other cystic fibrosis specialist and will cover all basic therapeutic areas. The conference is designed information on basic treatment, standards of care and effective therapies to medical and allied healthcare professionals. CFW is also planning an educational conference in Istanbul, Turkey December, 2012.
Novartis has partnered with Cystic Fibrosis Worldwide to help treat and educate cystic fibrosis patients. Cystic fibrosis (CF) is a life-threatening genetic disease that primarily affects children and young adults. Pseudomonas aeruginosa (Pa) lung infections are one of the main drivers of morbidity and mortality in CF patients, and the complexity of daily treatment reduces patientsÃ¢ ability to lead normal lives.
On July 22, 2011, Novartis received EU approval for TOBI® Podhaler®, a new dry powder formulation of tobramycin delivered in a convenient and portable breath-activated inhaler. TOBI Podhaler is the first approved dry powder formulation of tobramycin, an inhaled antibiotic for treating Pa lung infections in adults and children aged six years and older with cystic fibrosis. The EU approval follows other approvals in Chile (Nov. 2010), Canada (April 2011) and Colombia (July 2011), with the first launch in Canada in May 2011.
The unique dry powder formulation, developed using novel PulmoSphere® technology, is delivered in a convenient, portable, easy-to-use device that does not require a power supply. TOBI® nebulizer solution, the most widely used form of tobramycin, has to be administered with a nebulizer and requires power, refrigeration and cleaning and disinfection of the nebulizer after treatment.
Data submitted to the European health authorities show that with TOBI Podhaler, treatment is administered in five to six minutes instead of 20 minutes with TOBI. That is a 72% reduction in administration time with comparable efficacy. This does not take into account the additional time saved on assembling, dismantling and disinfecting nebulizer and compressor equipment.
Together, Norvartis and Cystic Fibrosis Worldwide are taking steps toward improving the quality of life and life expectancy of cystic fibrosis patients.
Cystic Fibrosis Worldwide (CFW) is a non-profit organization located in Massachusetts and Turkey. CFW is dedicated to improving quality of life and life expectancy for people living with Cystic Fibrosis (CF), a genetic life-threatening disease. Since inception in 2002, CFW has used a variety of programs to aid the CF community in Massachusetts, across the US, and throughout the world. With 67 member countries, CFWÃ¢s primary function is to spread information about the disease among scientists, medical professionals, caregivers, patients, and families and to act as a platform for the international exchange of information. In addition, CFW helps member countries, both developed and developing, by providing capacity-building tools in areas of governing, operating, and fundraising. To learn more about CFW, please visit http://www.cfww.org.
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group’s continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/9/prweb8819444.htm